Impact News +++ FDA official calls UniQures gene therapy a failed treatment for Huntingtons disease (CNBC) +++ UNIQURE Aktie +3,60%

MESOBLAST Aktie

>MESOBLAST Aktienkurs

1.34 EUR +6.4% (TradegateBSX)

Ask: 1.37 EUR / 1455 Stück

Bid: 1.29 EUR / 1552 Stück

Tagesumsatz: 4428 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MESOBLAST Aktie über LYNX handeln

Intraday

1 Jahr

>MESOBLAST Performance

1 Woche: -11,3%

1 Monat: -3,6%

3 Monate: -11,6%

6 Monate: +9,8%

1 Jahr: -8,8%

laufendes Jahr: -11,0%

>MESOBLAST Aktie

Name:

MESOBLAST LTD.

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000MSB8 / A0DNPW

Symbol/ Ticker:

LWB (Frankfurt)

Kürzel:

FRA:LWB, ETR:LWB, LWB:GR

Index:

Webseite:

https://www.mesoblast.com..

Profil:

Mesoblast Limited is a biotechnology company specializing in the development of allogeneic, or off-the-shelf, cellular medicines intended for the treatment of severe and life-threatening inflammatory ..
>Volltext..

Marktkapitalisierung:

1632.44 Mio. EUR

Unternehmenswert:

1636.88 Mio. EUR

Umsatz:

57.83 Mio. EUR

EBITDA:

-57.69 Mio. EUR

Nettogewinn:

-84.45 Mio. EUR

Gewinn je Aktie:

-0.07 EUR

Schulden:

116.63 Mio. EUR

Liquide Mittel:

112.17 Mio. EUR

Operativer Cashflow:

-63.29 Mio. EUR

Bargeldquote:

1.01

Umsatzwachstum:

1011.51%

Gewinnwachstum:

10.99%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MESOBLAST

Letzte Datenerhebung:

05.03.26

>MESOBLAST Kennzahlen

Aktien/ Unternehmen:

Aktien: 1288.51 Mio. St.

Frei handelbar: 66.6%

Leerverk. Aktien: -

Rückkaufquote: -9.46%

Mitarbeiter: 81

Umsatz/Mitarb.: 0.19 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 93.53%

Bewertung:

KGV: -

KGV lG: -

KUV: 27.13

KBV: 3.32

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 48.65%

Gewinnmarge: -146.03%

Operative Marge: -113.08%

Managementeffizenz:

Gesamtkaprendite: -13.17%

Eigenkaprendite: -18.27%

>MESOBLAST Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>MESOBLAST Chart & Kurs - Tradegate

>MESOBLAST News

27.02.26 - 09:33	Mesoblast misses H1 estimates (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 01:48	What′s going on with Mesoblast shares today? (Fool)
	This biotech was up almost 9% before sinking into the red. The post What's going on with Mesoblast shares today? appeared first on The Motley Fool Australia....

27.02.26 - 00:24	Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 (Fool)
	Mesoblast posts strong H1 FY2026 results on the back of Ryoncil®'s US launch and robust revenue growth. The post Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 appeared first on The Motley Fool Australia....

20.02.26 - 13:03	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire EN)
	NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025....

12.02.26 - 00:30	High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD (GlobeNewswire EN)
	NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah....

29.01.26 - 22:48	Could Mesoblast shares hit $4.45 in 2026? (Fool)
	Bell Potter thinks this biotech could be cheap and heading much higher. The post Could Mesoblast shares hit $4.45 in 2026? appeared first on The Motley Fool Australia....

29.01.26 - 03:00	This ASX 200 stock just reported a milestone quarter. So why are its shares falling? (Fool)
	Mesoblast shares slip after its quarterly update, as investors focus on cash flow and execution. The post This ASX 200 stock just reported a milestone quarter. So why are its shares falling? appeared first on The Motley Fool Australia....

29.01.26 - 01:00	Mesoblast posts revenue jump and new funding: Key takeaways for investors (Fool)
	Mesoblast posts strong Ryoncil sales and secures new funding, with cash reserves set for upcoming clinical milestones. The post Mesoblast posts revenue jump and new funding: Key takeaways for investors appeared first on The Motley Fool Australia....

27.01.26 - 00:48

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment (GlobeNewswire EN)

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1...

19.01.26 - 04:01	Mesoblast dips on confusion around FDA advice on stem cells for back pain (Market Herald)
	Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the…...

19.01.26 - 02:36	Mesoblast just cleared a key FDA hurdle. So why are investors exiting? (Fool)
	Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product. The post Mesoblast just cleared a key FDA hurdle. So why are investors exiting? appeared first on The Motley Fool Australia....

09.01.26 - 23:00	Markets in a Minute: Mesoblast, Alkane Resources shine (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 19:09	Mesoblast rises as Ryoncil sales climb 60% in December quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 04:30	Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M (Market Herald)
	Mesoblast (ASX:MSB) is back onto investors' radars after the slower Christmas period,…...

09.01.26 - 03:24	Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today (Fool)
	These shares are ending the week strongly. But why? The post Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today appeared first on The Motley Fool Australia....

09.01.26 - 01:01	Why are Mesoblast shares jumping 10% to a 52-week high? (Fool)
	This biotech is hitting new highs on Friday. Let's find out why. The post Why are Mesoblast shares jumping 10% to a 52-week high? appeared first on The Motley Fool Australia....

02.01.26 - 00:06	Mesoblast Announces Changes to Board of Directors′ Leadership Roles (GlobeNewswire EN)
	NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company....

30.12.25 - 03:12	Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today (Fool)
	These shares are having a good session on Tuesday. Let's see why. The post Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today appeared first on The Motley Fool Australia....

30.12.25 - 02:36	This ASX healthcare stock just changed its debt. Here′s why it matters (Fool)
	Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure. The post This ASX healthcare stock just changed its debt. Here's why it matters appeared first on The Motley Fool Australia....

30.12.25 - 01:00	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line (GlobeNewswire EN)
	Mesoblast has option to draw down up to US$125 million by June 30, 2026...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram